7-hydroxy-3',4',5'-trimethoxyisoflavone | 98469-92-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7-hydroxy-3',4',5'-trimethoxyisoflavone
• 英文别名: 7-hydroxy-3-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-4-one；7-Hydroxy-3',4',5'-trimethoxy-isoflavon；3',4',5'-trimethoxy-7-hydroxyisoflavone；7-hydroxy-3-(3,4,5-trimethoxy-phenyl)-chromen-4-one；7-Hydroxy-3-(3,4,5-trimethoxyphenyl)chromen-4-one
• CAS: 98469-92-2
• 化学式: C₁₈H₁₆O₆
• 分子量: 328.321
• InChiKey: SIQMOLXKVIRRAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7-hydroxy-3',4',5'-trimethoxyisoflavone 在 硫酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 25.0h， 生成 2-{[4-oxo-3-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-7-yl]oxy}acetic acid
  参考文献：
  名称：

  新型大豆苷元类似物和天冬氨酸体外抗流感活性

  摘要：

  基于中药（TCM）活性成分黄豆苷元的结构修饰合成了一系列新型异黄酮，并在体外评估了它们在MDCK细胞中对抗H1N1达菲耐药（H1N1 TR）病毒的抗流感活性线。其中，4-oxo-4H-1-benzopyran-8-carbaldehydes 11a-11g 是最有前途的，它们表现出与核苷类抗病毒剂利巴利文相比更好的活性和选择性。3-(4-Bromophenyl)-7-hydroxy-4-oxo-4H-1-benzopyran-8-carboxaldehyde (11c) 显示出最好的抑制活性 (EC50, 29.0 μM) 和选择性指数 (SI>10.3)。

  DOI：

  10.1002/cbdv.201400337
• 作为产物：
  描述：

  2',4'-bis(benzyloxy)-3,4,5-trimethoxychalcone 在 palladium on activated charcoal 盐酸 、 thallium(I) nitrate 、 氢气 、 三乙胺 作用下， 以 甲醇 、 氯仿 、 乙酸乙酯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 生成 7-hydroxy-3',4',5'-trimethoxyisoflavone
  参考文献：
  名称：

  Nishiyama, Kiyotoshi; Esaki, Sachiko; Deguchi, Ikuko, Bioscience, Biotechnology and Biochemistry, 1993, vol. 57, # 1, p. 107 - 114

  摘要：

  DOI：

文献信息

• 7-Hydroxy-benzopyran-4-one Derivatives: A Novel Pharmacophore of Peroxisome Proliferator-Activated Receptor α and -γ (PPARα and γ) Dual Agonists
  作者：Azadeh Matin、Navnath Gavande、Moon S. Kim、Nancy X. Yang、Noeris K. Salam、Jane R. Hanrahan、Rebecca H. Roubin、David E. Hibbs

  DOI：10.1021/jm900964r

  日期：2009.11.12

  Design, synthesis, and in vitro bioevaluation of a new class of potential dual PPARα and γ agonists discovered through a structure-driven design paradigm are described. The 7-hydroxy-benzopyran-4-one moiety (includes flavones, flavanones, and isoflavones) is the key pharmacophore of these novel molecules, exhibiting similarity to the core structure of both fibrates and thiazolidinediones. New lead

  描述了通过结构驱动设计范式发现的新型潜在的双重PPARα和γ双重激动剂的设计，合成和体外生物评价。7-羟基-苯并吡喃-4-酮部分（包括黄酮，黄烷酮和异黄酮）是这些新分子的关键药效​​基团，与贝特类药物和噻唑烷二酮的核心结构相似。从“保健食品”和合成类似物中鉴定出新的PPAR配体。总共筛选了77个分子，包括查耳酮，黄酮，黄烷酮，异黄酮和吡唑衍生物，并进行了双重激动剂的构效关系研究。化合物68，70，72，和76被鉴定为新型有效的PPARα和γ双重激动剂。这些新型分子可能会成为PPAR相关疾病（包括II型糖尿病和代谢综合征）未来的领先者。
• [EN] FLAVONOID PPAR AGONISTS<br/>[FR] AGONISTES FLAVONOÏDES DE PPAR
  申请人：UNIV SYDNEY

  公开号：WO2009026657A8

  公开（公告）日：2009-05-28
• Structural Modification and Optimisation of Hyperoside Oriented to Inhibit TGF-β-Induced EMT Activity in Alveolar Epithelial Cells
  作者：Ziye Gao、Mengzhen Xu、Chuanguo Liu、Kai Gong、Xin Yu、Kaihui Lu、Jiang Zhu、Haixing Guan、Qingjun Zhu

  DOI：10.3390/ph17050584

  日期：——

  Pulmonary fibrosis (PF) is a disease characterised by diffuse nonspecific alveolar inflammation with interstitial fibrosis, which clinically manifests as dyspnoea and a significant decline in lung function. Many studies have shown that the epithelial–mesenchymal transition (EMT) plays a pivotal role in the pathogenesis of pulmonary fibrosis. Based on our previous findings, hypericin (Hyp) can effectively inhibit the process of the EMT to attenuate lung fibrosis. Therefore, a series of hyperoside derivatives were synthesised via modifying the structure of hyperoside, and subsequently evaluated for A549 cytotoxicity. Among these, the pre-screening of eight derivatives inhibits the EMT. In this study, we evaluated the efficacy of Z6, the most promising hyperoside derivative, in reversing TGF-β1-induced EMTs and inhibiting the EMT-associated migration of A549 cells. After the treatment of A549 cells with Z6 for 48 h, RT-qPCR and Western blot results showed that Z6 inhibited TGF-β1-induced EMTs in epithelial cells by supressing morphological changes in A549 cells, up-regulating E-cadherin (p < 0.01, p < 0.001), and down-regulating Vimentin (p < 0.01, p < 0.001). This treatment significantly reduced the mobility of transforming growth factor β1 (TGF-β1)-stimulated cells (p < 0.001) as assessed by wound closure, while increasing the adhesion rate of A549 cells (p < 0.001). In conclusion, our results suggest that hyperoside derivatives, especially compound Z6, are promising as potential lead compounds for treating pulmonary fibrosis, and therefore deserve further investigation.